氯吡格雷、阿司匹林和他汀类药物基因多态性在心血管患者中的分布
摘要
关键词
全文:
PDF参考
Nyasinga J, Kyany’A C, Okoth R , et al. A six-member SNP assay on the iPlex MassARRAY platform provides a rapid and affordable alternative for typing major AfricanStaphylococcus aureustypes.[J]. Access microbiology, 2019,1(3):e000018.
余艳芳.基质辅助激光解析电离飞行时间质谱在结核分枝 杆菌耐药检测中的应用价值研究[J].实用心脑肺血管病杂 志,2021,29(10):7.
钟诗等.氯吡格雷抗血小板治疗个体化用药基因型检测指南解 读[J].中国实用内科杂志,2015(1):38-41.
彭文星,冯频频,石秀锦,等.阿司匹林抵抗的基因多态性及个体 化治疗[J].中国药房,2016,27(23):3.
Guan Z , Wu K , Li R, et al. Pharmacogenetics of statins treatment: Efficacy and safety[J]. Journal of Clinical Pharmacy and Therapeutics,2019,44(6).
Liu C C , Kanekiyo T , Xu H , et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy[D]. NATURE PUBLISHING GROUP,2013.
王丹,任经天,董铎,等.药品不良反应监测年度报告十年趋势分析[J].中国药物警戒,2020,17(5):276-283.
Chang M, et al. European Journal of Clinical Pharmacolo gy,2015,71(4):433-439.
Cresci S, et al. Circulation Cardiovascular Genetics, 2014,7(3):277.
USPSTF: Final Guidelines on Aspirin as CVD, Cancer Prevention. Medscape. April 11,2016.
阿司匹林在动脉硬化心血管疾病中的临床应用-中国专家共识(2005)[J].中国全科医学,2006,9(16):1339-1341.
Journal of Allergy & Clinical Immunology, 2004,113(4):771-775. [13] Thrombosis & Haemostasis, 2006,96(2):253-259.
Moran A , Gu D , Zhao D , et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.[J]. Circulation Cardiovascular Quality & Outcomes, 2010,3(3):243.
高辉,王杨,陈婉婷,等.SLCO1B1和APOE基因多态性与他汀类 药物疗效的相关性[J].实用医学杂志,2019,35(14):2300-2303.
Generaux GT, Bonomo FM, Johnson M, et al. Impact of SLCO1B1(OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins[J].Xenobiotica, 2011, 41(8): 639-651.
Wang C, Yan W, Wang H, et al. APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population[J]. Pharmacogenomics, 2019,20(14): 1021-1031.
DOI: https://doi.org/10.12346/pmr.v4i4.7113
Refbacks
- 当前没有refback。